US OptionsDetailed Quotes
ESPR241220C4500
- 0.13
- 0.000.00%
15min DelayClose Dec 13 16:00 ET
0.00High0.00Low
0.13Open0.13Pre Close0 Volume292 Open Interest4.50Strike Price0.00Turnover496.57%IV105.78%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.13Extrinsic Value100Contract SizeAmericanOptions Type0.2131Delta0.2067Gamma17.31Leverage Ratio-0.0350Theta0.0001Rho3.69Eff Leverage0.0008Vega
Esperion Therapeutics Stock Discussion
gone for good ? 😢
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
Esperion Therapeutics (NASDAQ: ESPR) has entered into a licensing agreement with Neopharm Israel for exclusive commercialization rights of NEXLETOL® and NEXLIZET® in Israel. The agreement includes an upfront payment, near-term milestone payments, and tiered royalties on product sales.
Under the agreement terms, Neopharm will rece...
1 min ago
Esperion Partners With Neopharm to Commercialize Nexletol® (Bempedoic Acid) and Nexlizet® (Bempedoic Acid and Ezetimibe) in Israel! Esperion Therapeutics Inc: Under Terms of Agreement, Esperion Will Receive an Upfront and Near-Term Milestone Payments
No comment yet